Some parts of this page is not supported on your current browser version. Please upgrade the browser to the latest.

U.S. markets open in 2 hours 45 minutes

Why Novavax (NVAX) Stock Fell 19% on Friday

Shares of biotech company Novavax NVAX plunged 19.6% in Friday trading after it delayed U.S. submission for its Covid-19 vaccine for the third time. Novavax said it now expects to apply for U.S. emergency-use authorization in the fourth quarter of this year.

NVAX has filed for emergency clearance in other regions like India, Indonesia & the Philippines, and it said it expects to submit its vaccine with the U.K., Europe, Australia, Canada & New Zealand in the third quarter.

Other news weighing on the stock is its second-quarter earnings results. The company reported a wider-than-expected loss of $4.75 per share; analysts were looking for a loss of $3.63 per share. Even though revenue skyrocketed 728% to $298 million, the top line still missed estimates of $387.9 million.

NVAX is up over 70% year-to-date.

Reach out

Find us at the office

Exel- Frazzitta street no. 61, 44925 Kingston, Norfolk Island

Give us a ring

Jovanny Boeding
+23 274 947 142
Mon - Fri, 10:00-21:00

Tell us about you